Allied Journal of Medical Research

All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.
Reach Us +1 (202) 780-3397

Commentary - Allied Journal of Medical Research (2022) Volume 6, Issue 12

Effects of SARS-CoV-2 mutations on the pathogenicity, structure, and function of the virus.

 Adam Emma*

Department of Biotechnology, College of Science, University of Tehran, Tehran, Iran

*Corresponding Author:
Adam Emma
Department of Biotechnology,
College of Science, University of Tehran,
Tehran, Iran

Received: 04-Nov-2022, Manuscript No. AAAJMR-22-84409; Editor assigned: 07-Nov-2022, PreQC No. AAAJMR-22-84409(PQ); Reviewed: 22-Nov-2022, QC No. AAAJMR-22-84409; Revised: 28-Nov-2022, Manuscript No. AAAJMR-22-84409(R); Published: 05-Dec-2022, DOI: 10.35841/aaajmr-6.11.156

Citation: Emma A. Effects of SARS-CoV-2 mutations on the pathogenicity, structure and function of the virus. Allied J Med Res. 2022;6(12):156

Visit for more related articles at Allied Journal of Medical Research


The COVID-19 outbreak, the third coronavirus pandemic, recently started in China. SARSCoV-2, the most recent coronavirus to be identified, is the sixth coronavirus to affect humans. Acute heart damage, severe pneumonia and RNAaemia together with glass turbidity are the major pathophysiology of SARS-CoV-2 infection. It has a single-stranded, 60-140 nm-diameter, 26-32 kbp-sized positive-sense RNA genome. Spike glycoprotein functions as the principal cell receptor for the membrane-bound aminopeptidase known as ACE2, which is responsible for viral pathogenesis. It has been established that a number of variables, including differing national quarantine laws and diverse racial or genetic backgrounds, may have an impact on the COVID-19 infection and fatality rates in specific regions.


SARS-CoV-2, COVID-19, Mutation, Pathogenicity, Pandemic disease.


Along with a number of other known and unknown variables and the genetic vulnerability of the host, COVID-19's varying clinical features are significantly influenced by the virus's own mutations and genetic variations. The SARS-CoV-2 genome is more stable than SARS-CoV or MERS-CoV, but compared to other RNA viruses, it exhibits a comparatively high dynamic mutation rate. It is noteworthy that some mutations exhibit unique regional patterns and can constitute founder mutations. These mutations undoubtedly contribute to viral genetic variability and, as a result of the genotype-phenotype relationship, can produce viruses with varying degrees of natural pathogenic fitness or, in the alternative, allow for viruses to rapidly change their antigenic makeup in order to circumvent host immunity and develop drug resistance, making them more contagious or lethal [1].

COVID-19 disease

The COVID-19 disease first appeared in China before spreading to practically every country in the world. Numerous nations throughout the world declared transportation restrictions and instituted quarantine as more cases were identified. Findings demonstrated that viral carriers included not only those with the disease who manifested a variety of symptoms but also those who did not. People who contract the virus occasionally do so without displaying any COVID-19 symptoms or even with only minor signs of the illness. However, the disease's symptoms might shift from mild to moderate to acute to severe, needing the patient's special care due to the development of acute respiratory distress syndrome and fluid retention [2].

According to epidemiological studies, age, demographics, the standard of clinical care, and other possibly unidentified elements all have a significant impact on clinical outcomes. A nutritious diet is also known to significantly contribute to reducing the onset of the disease's severe form by enhancing the immune system. Another element influencing the likelihood of COVID-19 development and the occurrence of a severe condition of the disease is the existence of certain underlying disorders in an individual. The virus can also result in bacterial pneumonia infections at the same time. Polymerase chain reaction molecular testing is done to verify the existence of the virus in the body. The second method uses chest computed tomography.


The SARS-CoV-2 virus is a member of the broad coronavirus family. The nidovirales family of viruses, which includes the coronaviruses, Roniviridae, and Arteriviridae families, is made up primarily of coronaviruses. The family of positive-sense single-stranded enveloped RNA viruses known as coronaviruses has genomes that range in size from 26 to 32 kilobases. This viral family, which comprises of the genera Alpha, Beta, Gamma, and Delta, includes several coronaviruses that affect both humans and animals. The human coronavirus was originally found in the middle of the 1960s. Seven human coronaviruses of the genera Alpha and Beta, including the Middle East respiratory syndrome coronavirus and severe acute respiratory syndrome coronavirus, have so far been found. They cause a variety of illnesses, such as the common cold and respiratory illnesses with mild and acute symptoms [3].

SARS-physiology CoV-2's

Structural and non-structural proteins in the infection genome are encoded in the open understanding casing. Right around 14 ORF have been sequenced in the SARS-CoV-2 genome up to this point. Sub-atomic examination of the new Covid showed that it has a solitary abandoned positive-sense RNA genome, which its size fluctuates between 29.8 kb and 29.9 kb, being 60-140 nm in measurement. Its genome is practically 80% homologous with SARS-CoV, and almost 96% of its qualities are imparted to the bat Covid. Every one of these ORFs is answerable for coding 17 proteins, both primary and non-underlying, that drive different cycles during the whole existence of the infection from its endurance to destructiveness power. The genome begins with 5′ UTR, which comprises of a variable number of ORFs, including ORF1ab, ORF3, ORF6, ORF 7a, ORF 8, and ORF10. SARS-COV 2 has eight frill proteins, encoded by ORF3a, ORF6, ORF7a, ORF7b, and ORF8 qualities, individually. These qualities contain imperative data for infection replication that has been safeguarded through progressive ages.

Mechanism of SARS-CoV-2 infection

The presence of S protein during the time spent pathogenesis of SARS-CoV-2 is basic. Spike protein utilizes a film bound amino peptidase called ACE2 as the essential cell receptor that ties to di-peptide peptidase-4 on the infection. ACE2 is generally communicated in the different organs, including the heart, lungs, gastrointestinal plot, and kidneys. Signal transmission through ACE2 is disturbed when extreme myocardial harm and brokenness in the lungs and different organs, for example, the kidneys and heart are actuated when the infection appends to the ACE2 receptor. Furthermore, the assurance of target cell explicitness is impacted by the S glycoprotein collaboration with cell receptors. The area of the receptor restricting area in S1 area of S not entirely set in stone by the design of every infection, which can be variable. The RBD locales are situated at N Terminal or C1 Terminal of S1. SARS-CoV-2 purposes a few peptidases as their cell receptors, despite the fact that their entrance happens even without any optional proteins [4].

The virus's SARS-CoV-2 mutations and associated changes

The rate of mutation for the RNA virus SARS-CoV-2 is probably 104 replacement of bp per year. Additionally, throughout each cycle of genome replication, changes could develop. DNA sequence comparison uses single-nucleotide polymorphism. It is beneficial for finding mutations in the coronavirus genome, where many mutations may be caused by an RdRp during genome replication, and can be employed for evolutionary analyses. The proteins that are mutated are those that are necessary for RNA replication and the spike protein, which binds to receptors, as was previously explained. This study noted that the genomes of SARS-CoV-2 European isolates, where the infection severity is typically more severe than in the United States, include the four mutations indicated above frequently [5].


The virus's genetic variations and mutations have a significant influence on the diverse clinical aspects of COVID-19 infection, in addition to a number of other known and unknown factors and the genetic vulnerability of the host. Overall, due mostly to the presence of asymptomatic people, it is now almost impossible to discover all of the SARS-CoV-2 mutations that have been observed and their relationship to pathological alterations. Notably, some patients with the aforementioned condition may be asymptomatic because of attenuated mutations in SARS-CoV-2, which needs to be clarified in further research. Numerous studies must also be conducted for additional participants in other areas/locations in order to confirm the findings. By exposing the genetic patterns of SARS-CoV-2 dissemination, such research could support patient-specific therapy.


  1. Devaux CA, Rolain JM, Colson P, et al. New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19. Int J Antimicrob Agents. 2020;55(5):105938.
  2. Indexed at, Google Scholar, Cross Ref

  3. Zhang X, Cai H, Hu J, et al. Epidemiological, clinical characteristics of cases of SARS-CoV-2 infection with abnormal imaging findings. Int J Infect Dis. 2020;94:81-7.
  4. Indexed at, Google Scholar, Cross Ref

  5. Wu D, Wu T, Liu Q, et al. The SARS-CoV-2 outbreak: what we know. Int J Infect Dis. 2020;94:44-8.
  6. Indexed at, Google Scholar, Cross Ref

  7. Wille M, Holmes EC. Wild birds as reservoirs for diverse and abundant gamma-and deltacoronaviruses. FEMS Microbiol Rev. 2020;44(5):631-44.
  8. Indexed at, Google Scholar, Cross Ref

  9. Chang TJ, Yang DM, Wang ML, et al. Genomic analysis and comparative multiple sequences of SARS-CoV2. J Chin Med Assoc. 2020;83(6):537-43.
  10. Indexed at, Google Scholar, Cross Ref

Get the App